other material
confidence high
sentiment positive
materiality 0.85
Fulcrum reports positive Phase 1b data for pociredir in SCD: 58% patients achieved HbF>=20% at 20 mg dose
Fulcrum Therapeutics, Inc.
- Mean absolute HbF increased 9.9% at Week 6 in 20 mg cohort (vs 5.6% in 12 mg); 7 of 12 patients (58%) achieved HbF ≥20%.
- Clear dose-response: >3.75-fold mean HbF induction at Week 12 (n=6) vs 2.4-fold in 12 mg cohort.
- Hemolysis markers improved at Week 6: indirect bilirubin -37%, LDH -37%, reticulocyte counts -33%.
- Pociredir well-tolerated with no treatment-related SAEs or discontinuations; dosed in 148 adults to date.
- Plans to submit IND for bone marrow failure syndromes (e.g., Diamond-Blackfan anemia) in Q2 2026.